Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agen...

Full description

Saved in:
Bibliographic Details
Published in:Science translational medicine 2016-10, Vol.8 (362), p.362ps17-362ps17
Main Authors: Pommier, Yves, O'Connor, Mark J, de Bono, Johann
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Clinical Trials, Phase I as Topic
DNA Damage
DNA Repair
Enzyme Inhibitors - pharmacology
Female
Genes, BRCA1
Humans
Male
Maximum Tolerated Dose
Mutation
Neoplasms - drug therapy
Neoplasms - pathology
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerases - chemistry
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Translational Medical Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
ISSN:1946-6234
1946-6242
DOI:10.1126/scitranslmed.aaf9246